Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 8
Real-World Decision-Making: Triplet vs Quadruplet in NDMM-TI
Panelists discuss how novel agents like iberdomide show promising efficacy and manageable toxicity in early-phase studies for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
Investigating Novel Agents and Extended Follow-Up Data
Emerging therapies such as iberdomide—a novel cereblon E3 ligase modulator—are showing promise in early-phase studies. When combined with carfilzomib and dexamethasone, iberdomide produces deep responses in newly diagnosed patients, with manageable toxicity.
Extended follow-ups of previously reported trials reinforce the durability of response seen with iberdomide-containing regimens. Investigators highlight the potential of this drug to enhance immunomodulatory activity while minimizing adverse effects through dose modifications.
Trial-in-progress updates like DREAMM-10 aim to further refine the dosing and safety profile of new agents like belantamab mafodotin. These efforts will be critical in expanding frontline options, particularly for patients unable to tolerate more traditional agents.
Related Content:
